Topiramate concentration in saliva: An alternative to serum monitoring

Michael V. Miles; Peter H. Tang; Tracy A. Glauser; Melody A. Ryan; Shellee A. Grim; Richard H. Strawsburg; Ton J. DeGrauw; Robert J. Baumann

doi:10.1016/S0887-8994(03)00048-1

Topiramate concentration in saliva: An alternative to serum monitoring

Michael V. Miles
, Peter H. Tang
, Tracy A. Glauser
, Melody A. Ryan
, Shellee A. Grim
, Richard H. Strawsburg
, Ton J. DeGrauw
, Robert J. Baumann

Research output: Contribution to journal › Article › peer-review

41 Scopus citations

Abstract

This study examines the relationship between serum and saliva topiramate concentrations, and attempts to determine if saliva may be a useful alternative to serum for therapeutic monitoring. Saliva and blood specimens were collected from 31 epilepsy patients (mean age 10.5 ± 6.0 years; range 2.5 years to 24.8 years), and topiramate concentrations were determined by fluorescence polarization immunoassay. One patient's results were omitted because the saliva concentration was below the limit of quantitation of the assay. A strong correlation exists between serum and saliva topiramate concentrations (adjusted r² = 0.97, n = 30, P < 0.0001). The mean fraction of saliva to serum concentration is 89.8% ± 12.1% (range 62.9% to 112.7%). The results of this study support the use of saliva as a viable alternative to serum for monitoring topiramate therapy. Topiramate concentration in saliva: an alternative to serum monitoring.

Original language	English
Pages (from-to)	143-147
Number of pages	5
Journal	Pediatric Neurology
Volume	29
Issue number	2
DOIs	https://doi.org/10.1016/S0887-8994(03)00048-1
State	Published - Aug 2003

Bibliographical note

Funding Information:
This study was supported in part by a grant from the Clinical Effectiveness Trustee Grant Program, Children’s Hospital Research Foundation, Cincinnati, Ohio.

Funding

This study was supported in part by a grant from the Clinical Effectiveness Trustee Grant Program, Children’s Hospital Research Foundation, Cincinnati, Ohio.

Funders	Funder number
Children’s Hospital Research Foundation
National Institute of Neurological Disorders and Stroke	U10NS077311

Keywords

Anticonvulsant monitoring
Antiepileptic Drug
Concentration
Saliva
Topiramate

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Neurology
Developmental Neuroscience
Clinical Neurology

Access to Document

10.1016/S0887-8994(03)00048-1

Cite this

@article{3add5566035e4e038af4c19d4563e640,

title = "Topiramate concentration in saliva: An alternative to serum monitoring",

abstract = "This study examines the relationship between serum and saliva topiramate concentrations, and attempts to determine if saliva may be a useful alternative to serum for therapeutic monitoring. Saliva and blood specimens were collected from 31 epilepsy patients (mean age 10.5 ± 6.0 years; range 2.5 years to 24.8 years), and topiramate concentrations were determined by fluorescence polarization immunoassay. One patient's results were omitted because the saliva concentration was below the limit of quantitation of the assay. A strong correlation exists between serum and saliva topiramate concentrations (adjusted r2 = 0.97, n = 30, P < 0.0001). The mean fraction of saliva to serum concentration is 89.8\% ± 12.1\% (range 62.9\% to 112.7\%). The results of this study support the use of saliva as a viable alternative to serum for monitoring topiramate therapy. Topiramate concentration in saliva: an alternative to serum monitoring.",

keywords = "Anticonvulsant monitoring, Antiepileptic Drug, Concentration, Saliva, Topiramate",

author = "Miles, \{Michael V.\} and Tang, \{Peter H.\} and Glauser, \{Tracy A.\} and Ryan, \{Melody A.\} and Grim, \{Shellee A.\} and Strawsburg, \{Richard H.\} and DeGrauw, \{Ton J.\} and Baumann, \{Robert J.\}",

note = "Funding Information: This study was supported in part by a grant from the Clinical Effectiveness Trustee Grant Program, Children{\textquoteright}s Hospital Research Foundation, Cincinnati, Ohio. ",

year = "2003",

month = aug,

doi = "10.1016/S0887-8994(03)00048-1",

language = "English",

volume = "29",

pages = "143--147",

number = "2",

}

TY - JOUR

T1 - Topiramate concentration in saliva

T2 - An alternative to serum monitoring

AU - Miles, Michael V.

AU - Tang, Peter H.

AU - Glauser, Tracy A.

AU - Ryan, Melody A.

AU - Grim, Shellee A.

AU - Strawsburg, Richard H.

AU - DeGrauw, Ton J.

AU - Baumann, Robert J.

N1 - Funding Information: This study was supported in part by a grant from the Clinical Effectiveness Trustee Grant Program, Children’s Hospital Research Foundation, Cincinnati, Ohio.

PY - 2003/8

Y1 - 2003/8

N2 - This study examines the relationship between serum and saliva topiramate concentrations, and attempts to determine if saliva may be a useful alternative to serum for therapeutic monitoring. Saliva and blood specimens were collected from 31 epilepsy patients (mean age 10.5 ± 6.0 years; range 2.5 years to 24.8 years), and topiramate concentrations were determined by fluorescence polarization immunoassay. One patient's results were omitted because the saliva concentration was below the limit of quantitation of the assay. A strong correlation exists between serum and saliva topiramate concentrations (adjusted r2 = 0.97, n = 30, P < 0.0001). The mean fraction of saliva to serum concentration is 89.8% ± 12.1% (range 62.9% to 112.7%). The results of this study support the use of saliva as a viable alternative to serum for monitoring topiramate therapy. Topiramate concentration in saliva: an alternative to serum monitoring.

AB - This study examines the relationship between serum and saliva topiramate concentrations, and attempts to determine if saliva may be a useful alternative to serum for therapeutic monitoring. Saliva and blood specimens were collected from 31 epilepsy patients (mean age 10.5 ± 6.0 years; range 2.5 years to 24.8 years), and topiramate concentrations were determined by fluorescence polarization immunoassay. One patient's results were omitted because the saliva concentration was below the limit of quantitation of the assay. A strong correlation exists between serum and saliva topiramate concentrations (adjusted r2 = 0.97, n = 30, P < 0.0001). The mean fraction of saliva to serum concentration is 89.8% ± 12.1% (range 62.9% to 112.7%). The results of this study support the use of saliva as a viable alternative to serum for monitoring topiramate therapy. Topiramate concentration in saliva: an alternative to serum monitoring.

KW - Anticonvulsant monitoring

KW - Antiepileptic Drug

KW - Concentration

KW - Saliva

KW - Topiramate

UR - https://www.scopus.com/pages/publications/0142248342

UR - https://www.scopus.com/pages/publications/0142248342#tab=citedBy

U2 - 10.1016/S0887-8994(03)00048-1

DO - 10.1016/S0887-8994(03)00048-1

M3 - Article

C2 - 14580658

AN - SCOPUS:0142248342

SN - 0887-8994

VL - 29

SP - 143

EP - 147

JO - Pediatric Neurology

JF - Pediatric Neurology

IS - 2

ER -

Topiramate concentration in saliva: An alternative to serum monitoring

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this